Marshall Wace’s Aura Biosciences AURA Stock Holding History

Marshall Wace’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-37,208	Closed	-$292K	–	2534
2024 Q1	$292K	Buy	+37,208	New	+$308K	﹤0.01%	2123
2022 Q1	–	Sell	-3,886	Closed	-$66K	–	3336
2021 Q4	$66K	Buy	+3,886	New	+$69.4K	﹤0.01%	3489

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Marshall Wace's AURA Position: Q2 2024 in Review

Marshall Wace sold out of Aura Biosciences (AURA) in Q2 2024, closing a stake of 37,208 shares — an estimated $292K sold.

Marshall Wace first reported a position in AURA in Q4 2021 and held it in 2 quarters. The position peaked at $292K in Q1 2024. 75 funds tracked by Wall St. Rank hold AURA as of Q2 2024.

Marshall Wace reported no remaining Aura Biosciences position as of Q2 2024 after selling out during the quarter.
Marshall Wace sold 37,208 Aura Biosciences shares in Q2 2024, an estimated $292K.
Marshall Wace first reported a position in Aura Biosciences in Q4 2021 and held it in 2 quarters.
Marshall Wace's Aura Biosciences position peaked at $292K in Q1 2024.
75 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.